68-2

30/110

122Osaka, Japan). A p < 0.05 was considered statistically significant, except when a p < 0.0083 was consid-ered significant for multiple comparisons among pain scores at four time points.Comparison between AMNV and FCV in the total cohortBy searching medical records, we identified a total of 1,183 patients who were diagnosed with HZ. We divided them into six groups based on the anti-herpetic agent therapy, including AMNV, FCV, VACV, vidarabine (Ara-A), acyclovir (ACV), and no therapy (Figure 1). Among them, we identified 152 and 141 patients who were treated with AMNV and FCV, respectively. After excluding 9 and 10 patients from AMNV- and FCV-treated patients, respectively, according to the above-mentioned exclusion criteria, we finally investigated a total of 274 patients, including 143 AMNV-treated patients and 131 FCV-treated patients (Figure 1). Baseline clinical characteristics and primary/secondary clin-ical outcomes in the total cohort are shown in Table 1　Clinical characteristics and primary/secondary clinical outcomes in the total cohort (n = 274)Clinical characteristicsAge (years)Sex; Males and FemalesAntiherpetic agents, AMNV and FCVEarly and Late visitorsAntibiotic therapySteroid userImmunocompromised state Antidepressant userRash locationsPrimary clinical outcomesRequirements of NSAIDsNRS pain score at Day 0NRS pain score at Day 3-4NRS pain score at Day 7NRS pain score at Week 2-3Secondary clinical outcomesPHNData are shown as Mean ± SD (Range), Median (Interquartile Range)［Range］, or Number (%), and compared between patients with unpaired t test, Mann-Whitney U test, or Pearson’s chi-square test.AMNV, amenamevir; FCV, famciclovir; V, trigeminal; C, cervical; TU, upper thoracic (T1-8); TL, lower thoracic (T9-12); L, lumbar; S, sacral; NSAIDs, non-steroidal anti-inflammatory drugs; NRS, numerical rating scale; PHN, postherpetic neuralgia Table 1. In the total cohort, the NRS pain score increased significantly at Day 3-4, but significantly decreased by Week 2-3, compared with Day 0 just before treatment (Figure 2). Seventy patients out of 274 (25.5%) required NSAIDs to relieve acute HZ pain.First, we compared clinical characteristics and primary/secondary clinical outcomes between 143 AMNV-treated patients and 131 FCV-treated patients. AMNV-treated patients were significantly younger and included significantly more early visi-Males, 120 (43.8) / Females, 154 (56.2)AMNV, 143 (52.2) / FCV, 131 (47.8)Early, 150 (54.7) / Late, 124 (45.3) V, 75 (27.4); C, 52 (19.0); TU, 59 (21.5); TL, 43 (15.7); L, 25 (9.1); S, 20 (7.3) Figure 1　Flow chart for study subject selection65.3 ± 15.9 (22-98）27 (9.9)38 (13.9)49 (17.9)15 (5.5)70 (25.5)2 (1, 3) ［0-10］2 (1, 4) ［0-10］2 (0, 4) ［0-10］0 (0, 2) ［0-10］29 (10.6)Results